Online first
Case report
Published online: 2024-08-13
Diagnosis and treatment options for inclusion body myositis — a case report
1
, 1
, 1
Abstract
Inclusion body myositis (IBM) is a progressive inflammatory myopathy. In the article, we describe the diagnosis of myopathy and long-term observation in a patient with IBM. In the discussion, we explore available IBM treatment strategies based on the current literature review.
Keywords: inclusion body myositisIBM treatment
References
- Callan A, Capkun G, Vasanthaprasad V, et al. A Systematic Review and Meta-Analysis of Prevalence Studies of Sporadic Inclusion Body Myositis. J Neuromuscul Dis. 2017; 4(2): 127–137.
- Greenberg SA. Pathogenesis of inclusion body myositis. Curr Opin Rheumatol. 2020; 32(6): 542–547.
- Kierdaszuk B. Wtrętowe zapalenie mięśni. In: Kostera-Pruszczyk A, Chromik-Potulska A. ed. Choroby nerwowo-mięśniowe. PZWL, Warszawa 2023: 236–237.
- Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin. 2014; 32(3): 629–46, vii.
- Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain. 1989; 112 ( Pt 3): 727–747.
- Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995; 38(5): 705–713.
- Haczkiewicz K, Sebastian A, Piotrowska A, et al. Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series. Rheumatol Int. 2019; 39(7): 1291–1301.
- Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008; 70(6): 418–424.
- Naddaf E, Barohn RJ, Dimachkie MM. Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics. 2018; 15(4): 995–1005.
- Pluk H, van Hoeve BJA, van Dooren SHJ, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013; 73(3): 397–407.
- Herbert MK, Pruijn GJM. Novel serology testing for sporadic inclusion body myositis: disease-specificity and diagnostic utility. Curr Opin Rheumatol. 2015; 27(6): 595–600.
- Amlani A, Choi MY, Buhler KA, et al. Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis. Front Immunol. 2019; 10(1): 745–14.
- Skolka MP, Naddaf E. Exploring challenges in the management and treatment of inclusion body myositis. Curr Opin Rheumatol. 2023; 35(6): 404–413.
- Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001; 56(3): 323–327.
- Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med. 2016; 374(7): 664–669.
- Ashton C, Paramalingam S, Stevenson B, et al. Idiopathic inflammatory myopathies: a review. Intern Med J. 2021; 51(6): 845–852.
- Badrising UA, Maat-Schieman MLC, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol. 2002; 51(3): 369–372.
- Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995; 45(7): 1302–1304.
- Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011; 134(Pt 11): 3176–3184.
- Breithaupt M, Schmidt J. Update on treatment of inclusion body myositis. Curr Rheumatol Rep. 2013; 15(5): 329.
- Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology. 1994; 44(8): 1516–1518.
- Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997; 48(3): 712–716.
- Walter MC, Lochmüller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000; 247(1): 22–28.
- Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1998; 65(1): 107–110.
- Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002; 58(2): 326.
- Dobloug C, Walle-Hansen R, Gran JT, et al. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol. 2012; 30(6): 838–842.
- Arnardottir S, Alexanderson H, Lundberg IE, et al. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med. 2003; 35(1): 31–35.
- Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009; 10(4): 178–184.
- Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve. 1997; 20(10): 1242–1248, doi: 10.1002/(sici)1097-4598(199710)20:10<1242::aid-mus6>3.0.co;2-c.
- Naddaf E. Inclusion body myositis: Update on the diagnostic and therapeutic landscape. Front Neurol. 2022; 13: 1020113.
- Jørgensen AN, Jensen KY, Nielsen JL, et al. Effects of blood-flow restricted resistance training on mechanical muscle function and thigh lean mass in sIBM patients. Scand J Med Sci Sports. 2022; 32(2): 359–371.
- Mohannak N, Pattison G, Radich B, et al. Exploring the efficacy of the expiratory muscle strength trainer to improve swallowing in inclusion body myositis: A pilot study. Neuromuscul Disord. 2020; 30(4): 294–300.
- Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis. http://www.clinicaltrials.gov/ct2/show/ NCT01519349.
- Amato AA, Hanna MG, Machado PM, et al. RESILIENT Study Extension Group. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021; 96(12): e1595–e1607.
- Benveniste O, Hogrel JY, Belin L, et al. Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatol. 2021; 3(1): e40–e48.
- Capkun G, Callan A, Tian H, et al. Burden of illness and healthcare resource use in United States patients with sporadic inclusion body myositis. Muscle Nerve. 2017; 56(5): 861–867.
